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386 T.O. Hirche et al. / Journal of Cystic Fibrosis 9 (2010) 385–399travel and at the destination, and issues specific to immunocompromised travellers. People with CF should be encouraged to consult with their CF
centre prior to travel to another country. The CF centre can advise on the necessary preparation for travel, the need for vaccinations, essential
medications that should be brought on the trip and also provide information relating to CF care in the region and plan of action in case of an
emergency.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Travelling; Holidays; Vacation
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 386
1.1. Methodology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387
2. Preparation before travelling. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387
2.1. Medical assessment and counselling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387
2.2. Air travel and staying at high altitude . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387
2.3. Predicting hypoxia at altitude . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
2.4. Air travel and oxygen supplementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
2.4.1. Prior to departure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 388
2.4.2. Assistance at the airport . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
2.4.3. Oxygen supplementation during air travel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
2.5. Prevention of travel related infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
2.5.1. General considerations on routine vaccinations in CF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 389
2.5.2. Specific travel vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390
2.5.3. Malaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390
2.6. Destination: where to go and not to go . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390
2.6.1. Lung infection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390
2.7. Infrastructure abroad (patient organisations, CF competence, hospitals) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391
2.8. CF health/travel insurance (incl. repatriation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391
2.8.1. European Union, Iceland, Liechtenstein, Norway and Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . 391
2.8.2. Travelling to non-EU countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 391
2.8.3. Repatriation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392
2.9. Specific documents (customs, forms, medical letter) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 392
3. During the journey and on site . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
3.1. Transportation and storage of medications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
3.2. Routine therapy and medication . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
3.3. Airway clearance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394
3.4. Prevention of salt depletion and dehydration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394
3.5. Physical activities and sports . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394
3.6. Prevention of P. aeruginosa infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
3.6.1. From the environment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
3.6.2. Patient-to-patient transmission. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
4. Specific recommendations for immunocompromised travellers/organ recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
4.1. Diseases related to travel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 396
4.2. Drug interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397
4.3. Vaccination under immunosuppression. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 397
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3971. Introduction
The increased life expectancy and improved quality of life
over the past three decades enable people with CF to participate
in every aspect of modern life, including tourism. The wish to
travel should be respected and supported depending on the
patient's state of health. The risks related to travel can be higher
for persons with CF than for healthy people. This may be most
challenging if the individual is travelling in a country withoutspecialized CF care. Detailed preparation along with prior
medical screening and advice is important to assure safe and
comfortable travel. CF caregivers are increasingly confronted
with travel-related questions from CF patients, a fact that is also
reflected in the growing number of inquiries about this issue to
the web-based ECORN-CF expert advice (www.ecorn-cf.eu).
Several guidelines have been written to assist CF caregivers
in the evaluation and monitoring of patients and the prevention
of clinical deterioration (available at www.ecfs.eu) [1–8].
People with CF need to be well prepared for travel and
should consult their CF centre team when considering a
trip in another country.
If trouble develops during the trip, individuals with
CF should contact their home CF centre initially.
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specifically related to travel.
The aim of this document is to provide guidance for travel
for people with CF and to assist them to responsibly plan the
stay abroad. We hope that these recommendations will be
adopted by all European CF centres to provide a basis for
improved patient care. It may be necessary to specifically train
the care team members in giving educated advice for travel
related questions based on the information given in this
overview.
1.1. Methodology
Within the international expert advice system of the
ECORN-CF project, many questions from patients and care
team members were asked related to the topic “travelling with
CF” and it proved to be difficult to assess the quality of answers
since no commonly accepted guideline on this topic was
available. Therefore this topic was chosen as a “consensus
statement” theme by the ECORN-CF study group. Following a
systematic review of the literature (search terms: CF AND/OR
chronic lung disease AND travelling AND/OR vacation AND/
OR holiday AND/OR sports), subtopic-specific working groups
developed first drafts of manuscript modules. These drafts were
then further developed according to a modified (simplified to
two iterations) Delphi procedure among all authors listed. If
evidence was lacking and in all situations where unanimous
consensus could not be reached, agreement among the authors
was achieved during consensus conferences which took place in
Frankfurt, Germany (November 5, 2008) and Prague, Czech
Republic (October 6 and 7, 2009), involving all members of the
ECORN study group.
2. Preparation before travelling
2.1. Medical assessment and counselling
In preparation for their stay abroad, patients need to be aware
that a CF centre might not always be close by, which can be
crucial in case their condition is deteriorating. If trouble
develops during the trip, individuals with CF should contact
their home CF centre initially.
CF centres should provide a thorough pre-holiday/pre-travel
medical assessment for each patient before agreeing that they
are fit to travel. There are few absolute contra-indications for
travel, but it is advisable that CF individuals consider how travel
will impact them and prepare appropriately. Prior to departure,
clinical status should be optimized. Some patients achieve this
with intensive treatment with intravenous antibiotics for two/
three weeks prior to travelling.
Patients may travel to different climates and the associated
risks of dehydration may be most prominent for individuals
with CF but exposure to high ozone concentrations, pollutants,
infectious agents (via air, food, and poor hygiene) may be
greater in a person with a chronic disease such as CF.
There are logistic issues to consider aswell, such as availability
of time, space and equipment for therapy, appropriate storage ofdrugs, and access tomedical care. Travel may bring about fatigue,
stress, and motion sickness. Patients may engage in activities
different from their usual ones. Occasionally, caregivers have to
advise that a person with CF is medically unfit to travel and to
refuse to sign insurance forms. Unless the trip is to accessmedical
treatment, patients with an unstable condition such as acute
pulmonary exacerbation, haemoptysis, gastrointestinal obstruc-
tion, or uncontrolled diabetes should postpone their travel until
their medical condition has stabilised.2.2. Air travel and staying at high altitude
Air travel and/or staying at high altitude need to be
highlighted because these conditions expose the individual to
a lower atmospheric pressure (see table “Correlation between
altitude, air pressure and oxygen content” at http://ecorn-cf.eu/
index.php?id=265&L=8). The partial pressure of oxygen is
inversely proportional to the altitude, hence, alveolar partial
pressure falls with increasing altitude, causing patients to be
more at risk of serious desaturation and hypoxaemia. In patients
with more severe lung disease, air travel or a stay at high altitude
may lead to hypoxia below a PaO2 of 6,6kPa (50 mmHg),
which is considered a significant threshold [9].
Commercial aircraft operate at different cabin altitudes and
pressures ranging from 300 m (1000 ft) to 3000 m (10,000 ft).
The Joint Aviation Authority has restricted the mean cabin
altitude to 2438 m (8000 ft). This will affect the inspired oxygen
available in the cabin, which ranges from 14.7% to 16.8%,
depending on the airline and aircraft (compared to 21% at sea
level). The current guidelines of the American Thoracic Society
(ATS) and British Thoracic Society (BTS) recommend that an
arterial oxygen tension (PaO2) of N6.6k Pa (50 mm Hg) be
maintained during flight in patients with chronic lung disease
[10,11].
The effects of short episodes of hypoxemia in subjects
adapted to chronic hypoxemia are unclear. It was shown that
people with CF can tolerate PaO2 values below 6.6kPa
(50 mm Hg) for several hours without cardiac decompensation
or cerebral symptoms, which suggests that BTS guidelines may
not be fully applicable in these patients. It can be assumed that
CF patients are adapted to intermittent severe hypoxia,
especially during exercise [12]. It is noteworthy that individuals
with CF usually carry no cardiovascular risk and are, on
average, younger than patients with chronic obstructive
pulmonary disease. Indeed, just considering a PaO2 cut-off for
requiring supplemental oxygen during a flight is an ‘oversim-
plification’. Ideally one should take into account the degree of
hyperventilation that the patient will be able to sustain as well as
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determine oxygen delivery to the tissues. Special attention has
to be paid to patients with severe bronchial collapse or
obstruction, since they may not be able to compensate for
hypoxia by hyperventilation [12]. Patients with liver cirrhosis
and oesophageal varices may be at higher risk for bleeding
during extended flights or stay at high altitude [13].
Absolute contra-indications for air travel—unless it is a
medical transport for life-saving procedures—could include:
severe respiratory insufficiency, right heart failure or hemo-
dynamic instability. Patients with a previous pneumothorax
should wait for 6 weeks after definitive surgical intervention
[11].Table 1
Factors to consider when recommending supplemental oxygen.
Medical history
Stability of pulmonary disease
Previous experiences (symptomatic on previous holidays)
Duration of flight
Duration of holiday
Destination, altitude, activity
Physical examination
Lung function tests
Blood gas analysis
Arterial oxygen saturation
Results of hypoxic challenge test
For CF patients, duration of flight and patient condition are
the main predictors of medical safety during air travel.
All people with CF should discuss air travel with their
CF doctor.
Prediction of in-flight oxygen may be helpful especially
in individuals with CF who have severe lung disease,
co-morbidity with other conditions worsened by
hypoxemia, pre-existing requirement for oxygen, or a
history of air travel intolerance.2.3. Predicting hypoxia at altitude
Most data on flight associated hypoxia are not derived from
studies in CF individuals but have been extrapolated from
other chronic obstructive lung diseases. In the past, several
tests to measure patients' flight eligibility have been developed
and evaluated [14–23]. Currently, exposure to a hypobaric
chamber or hypoxic challenge at low altitude is used to mimic
in-flight conditions [12,24]. The tests should be performed
when the patient is clinically stable and relatively close to (not
earlier than three months before) the planned travel.
Exposure to a hypobaric chamber provides good simulation
of in-flight conditions; however, it is not always readily
available, not tolerated by all patients and expensive. The
Aerospace Medical Association and the British Thoracic
Society recommend the hypoxia inhalation test (HIT), which
involves breathing a hypoxic gas mixture (15% oxygen in a
nitrogen balance) for 20 min with the aim of predicting
hypoxemia at the maximum allowable cabin pressure altitude
of 2438 m (8000 ft) [11,25]. In-flight oxygen therapy is
recommended if the HIT PaO2 falls below 6.6–7.4 kPa (50–
55 mmHg) [26] (see table “Simulated altitudes by different
FiO2” at http://ecorn-cf.eu/index.php?id=265&L=8).
Several authors have shown that both hypobaric chamber
and HIT are safe and predict PaO2 at altitude of patients with
obstructive lung disease accurately [17,27]. However, both tests
are performed in a stable environment and may not fully
represent the physical stress and environmental variability of air
travel, particularly over longer flights [17,28–31]. The addition
of a 50 m walk test during the HIT significantly worsened
hypoxemia in patients with respiratory diseases [32]. On the
other hand, the majority of patients who would have qualified
for the use of in-flight oxygen following HIT travelled safely
without additional oxygen [24,26,33]. Therefore, a HIT PaO2
b7.4 kPa (55 mm Hg) does not automatically indicate the need
for in-flight oxygen therapy. Rather, it should prompt aninformed discussion between the patient and clinician about the
benefits and risks of flying with or without supplemental
oxygen (Table 1). Recently, it was reported that patients with an
FEV1 persistently above 55% predicted are very unlikely to
have significant desaturation during air travel [24,34]. Howev-
er, if flight eligibility of patients is in doubt, the tests described
above should be performed. If those tests are not available (e.g.
due to geography and resource issues), it is recommended to
prescribe oxygen during flight for patients at possible risk of
desaturation.
Further research is required to determine how the degree and
duration of hypobaric hypoxia will influence the relative risk of
adverse events in CF patients.2.4. Air travel and oxygen supplementation
2.4.1. Prior to departure
Airlines usually require the patient to carry a prescription for
oxygen at all times. Many have their own airline-specific
medical form the doctor must complete. These are usually valid
for one year and should include information on the passengers'
fitness to travel and his/her ability to operate the oxygenation
device and respond appropriately to its alarms. The phases of
the flight during which oxygen is medically necessary (taxi,
takeoff, cruise, and landing) should be specified. Since many
carriers charge a fee for supplemental oxygen, the insurance
provider of the individual with CF should be contacted in
advance to determine coverage for oxygen needs while
travelling. Furthermore, the patient must contact the local
providers for oxygen use during any stopover(s) and at the final
destination. This contact can usually be set up by the oxygen
provider in the home country.
If a person with CF needs in-flight oxygen (such as all
persons on long-term oxygen therapy [LTOT]), the
airline should be informed beforehand.
389T.O. Hirche et al. / Journal of Cystic Fibrosis 9 (2010) 385–3992.4.2. Assistance at the airport
According to recent EU rules, people with reduced mobility
should have the same access to air travel as other passengers
(EU regulation no. 1107/2006). Under anti-discrimination
legislation, airlines and tour operators are forbidden to refuse
passengers service on the basis of reduced mobility unless
“duly justified” by safety reasons. Therefore, since 2008,
disabled people are entitled to receive free-of-charge assis-
tance in all European airports as well as on board planes taking
off in the EU. Travellers should inquire with their airline prior
to departure which services they offer free of charge. The list
of responsibilities for airports and airlines—for which they
will have to bear costs—includes providing the relevant
infrastructure for disabled passengers as well as carriage for
wheelchairs and medically necessary equipment. Some air-
lines offer special ground services such as separate check-in,
priority boarding, etc. Travellers with limited mobility should
contact the airline at least 48 h prior to departure about any
assistance necessary, which will then be arranged by the
airport personnel.Table 2
Recommended vaccines for travellers [5].
Routine vaccinations Diphtheria, tetanus, pertussis
Diphtheria, tetanus, pertussis adolescent
booster a
Hepatitis B a
Haemophilus influenzae type B
Human papillomavirus (HPV) a
Influenza b
Measles, mumps, rubella
Pneumococcal disease a
Poliomyelitis
Rotavirus a
Tuberculosis (BCG) c
Varicella a
Selective use for travellers Hepatitis Ab/d
Typhoid fever
Yellow fever d
Cholera
Japanese encephalitis d
Tick-borne encephalitis
Meningococcal ACWYd
Rabies
Mandatory vaccinations for
some countries
Yellow fever d
Meningococcal ACWYd
Poliomyelitis
a Vaccines being currently introduced in some countries.
b Routine for certain risk groups, selective for travellers.
c No longer routine in most industrialised countries.
d Not included in the routine immunisation program in most countries.2.4.3. Oxygen supplementation during air travel
For travellers who require in-flight supplemental oxygen,
each airline has its own policy for on-board oxygen transport
and in-flight oxygen usage (for comprehensive information see
http://www.european-lung-foundation.org). It is recommended
that the airline should be notified at the time reservations are
made and again 48 h before flight time that the patient intends to
travel with oxygen.
If therapeutic oxygen is required for use during the flight
there are several options. By international law, liquid oxygen is
not permitted on board any aircraft. Most European airlines
allow passengers to carry and use a small gaseous oxygen
cylinder of not more than 2 l capacity (UN-1072, 200 bar).
However, this service is prohibited on flights to/from/via the
USA, Canada and Mexico. The oxygen cylinder must be stowed
in a solid case under the front seat during flight, if possible also
during usage. Some airlines will allow empty oxygen
equipment to be stowed in the baggage, but it must be verified
as empty and the regulator removed. It is important to check
with the airline ahead of time if they will allow empty systems/
tanks as stowed or checked baggage.
Most airlines provide oxygen on board their aircraft at an
additional cost depending on the routing (continental or
intercontinental flights). A separate charge usually applies for
each flight. The method of oxygen delivery (continuous,
demand system) and maximum flow rate vary between airlines
and might be limited. The newest portable equipment available
for oxygen users are Portable Oxygen Concentrators (POCs).
These units are lightweight and can run on electrical or battery
power. Since May 2009, POCs are allowed on all flights
originating or ending in the United States. A limited number of
POCs have been approved by the Department of Transporta-
tion for use during air travel (9/2009: Inogen One, AirSep
Lifestyle, AirSep Freestyle, SeQual Eclipse and Respironics
EverGO). The POC will need sufficient battery power to coverpre-flight, in-flight and post-flight time, including potential
delays.2.5. Prevention of travel related infection
Routine hygienic precautions have to be followed carefully
and hydroalcoholic solutions for hand disinfection should be
carried and used. Each traveller should be up to date with their
routine vaccinations according to age, as recommended by the
national vaccination schedule. Moreover, additional vaccina-
tions and safety measures may be recommended for interna-
tional travel, depending on the destination (Table 2).
2.5.1. General considerations on routine vaccinations in CF
National recommendations and strategies of immunisation
should be applied to all subjects including those with CF.
However, individuals with CF may have easily escaped normal
national immunisation programs, being absent from school and
admitted to the hospital for treatment in the past and so run a
higher risk of incomplete and delayed immunisation than healthy
children [5,35].
Before travelling, a vaccination review should be done, and
any gaps in the vaccination schedule should be remedied by catch-
up. Specific antibody monitoring is helpful in determining the
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guidelines should be followed. Tuberculosis is not frequently a
problem in CF patients, but diagnosis is obvious. Since occult TB
could be reactivated after transplantation, immunisation in accord
with established local practice seems logical [5].When travelling, additional immunisations may be
needed, depending on the destination. The required
immunisations should be discussed with the CF doctor.2.5.2. Specific travel vaccines
Influenza vaccine: recommended annually for all CF patients
aged 6 months and older. This should also be applied to
travellers (typically November–February in the Northern
Hemisphere, April–September in the Southern Hemisphere
and throughout the year in the tropics).
Inactivated hepatitis A vaccine and recombinant hepatitis B
vaccine: this has been shown to be safe and efficacious in
preventing infection [37]. Most adult CF patients might not
have been vaccinated, even in countries that recommend
vaccination. Several studies have shown a higher risk of fatal
hepatitis A and B infection when exposed to these viruses
during travel and in patients with chronic liver disease and
discussed the rationale of vaccinating these patients [5,37]. As
some evidence of liver abnormality can be found in up to 92%
of CF patients, they should all be considered a target group for
vaccination. [38]. Hepatitis A infection is one of the most
common vaccine-preventable travel infections and vaccination
should be recommended to all those travelling to Southern
Europe, Africa (including North Africa), South America, Asia
and other overseas destinations. Transmission can occur
through direct person-to-person contact, contaminated water,
ice, shellfish, fruits, vegetables and other foods contaminated
during handling, even at “standard” tourist accommodations.
Although the risk of hepatitis B infection for international
travellers is generally low (except for certain countries with a
high prevalence), hepatitis B infection can, in contrast to the
rather benign character of hepatitis A infection, result in a
chronic carrier state and disease. Modes of transmission include
contaminated injection or other equipment used for health care,
dental and cosmetic procedures (tattooing and piercing), and,
less known, unprotected sex and open skin lesions. CF travellers
are more likely to need medical procedures during travel.
Hepatitis A vaccine is recommended for subjects older than
one year. The combined hepatitis A and B vaccine, also
recommended in subjects older than one year, offers dual
protection in a simple schedule (0, 1, and 6 months) [37,39,40].
Yellow fever: transmitted by mosquitoes, and endemic in
certain areas of Africa and South America (consult WHO
country map). In some countries, proof of vaccination is
required for entry. Yellow fever vaccine is a live virus vaccine
that can be administered to subjects aged one year and older (in
some exceptional cases also to infants aged 6–12 months). One
injection offers a ten-year period of protection [39].
Other additional vaccinations, such as typhoid vaccine,
cholera vaccine, tick-borne encephalitis vaccine, Japanese
encephalitis vaccine, meningococcal ACWY vaccine, and
rabies may be recommended for international travel. Additional
information about these vaccinations can be found on the WHO
web site [39].2.5.3. Malaria
One of the most serious life-threatening diseases affecting
international travellers. No vaccination is available yet. Detailed
information about malaria risk and advice for chemoprophy-
laxis, as well as precautions for avoiding mosquito bites
(application of DEET), is presented on the WHO web site.
Medications used for prophylaxis in normal subjects such as
mefloquine (Lariam®) and atovaquone/proguanil (Malarone®)
can cause some digestive intolerance but do not seem to be
hepatotoxic [39].2.6. Destination: where to go and not to go
Choosing a travel destination depends heavily on the
interests and readiness to assume risk of the patient and his/
her relatives. Therefore, this document does not provide a list of
recommended countries. In deciding on a destination, however,
travellers should consider their current status as well as potential
complications of their CF. Therefore, regions and countries with
a good infrastructure and a high standard of health care should
be given priority. Patients need to make themselves familiar
with the facilities available in the country to which they are
travelling. It is recommended that they consult the travel
agency, the local health care arrangements and their CF centre
prior to the journey. Patients should be informed about personal
safety, required vaccinations, health insurance, local medical
supply, AC adapter etc.
Ideally, comprehensive CF care via CF centres should be
available in the destination country. This is the case particularly
in the countries of the EU as well as Turkey, Israel, North
America, the Far East, Australia and New Zealand. Travelling
to non-EU countries in Eastern Europe, Russia, Mediterranean
Maghreb countries, the Caribbean, South America (moderate or
subtropical climate), or Islands in the Indian or Pacific Oceans is
possible but requires detailed planning and information about
regional/seasonal particularities and precautions. Strategies for
dealing with potential complications (such as compiling lists of
possible contact points, suitable transport services, etc.) should
be developed prior to departure.
There is no official list available of specific countries/regions
that CF patients should avoid visiting. In most cases, a good
preparation of the journey is more important than the actual
travel destination. However, patients should be aware of the
risks involved in travelling to regions with uncertain medical
service and hygienic standards; this includes, for example,
regions with humid, tropical climate in South and Middle
America, Africa and South-East Asia.
2.6.1. Lung infection
In the recent past, there have been several case reports on the
specific risk for CF patients travelling to remote areas in tropical
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warnings is the high frequency of Burkholderia pseudomallei,
which occurs predominantly in fresh water and damp earth in
Thailand, Malaysia, Vietnam and Northern Australia. This
pathogen is known to cause symptomatic infections even in
healthy people. There have been reports on severe pneumonias
of CF patients who travelled to these regions [41–43].Certain areas bear a significant risk of specific infections,
including Burkholderia pneumonia.2.7. Infrastructure abroad (patient organisations,
CF competence, hospitals)
Reliable information with respect to CF expertise and
infrastructure (specialized care) at the intended destination is
not always easy to find, often requires intensive research on the
internet and may include contacting national patient associations
or even specific clinicians within the worldwide CF community.
The Cystic Fibrosis Worldwide (CFW) web site provides a
rather comprehensive list of most patient organisations across
the world, including addresses and contact partners, with a
focus on Europe, Russia, North Africa, South Africa, New
Zealand, Australia, the United States and South America. Some
parts of the world where no CF infrastructure is yet available are
not included; however, contact partners are given for many of
the countries that currently do not have a stable patient
association (http://www.cfww.org/members/).
CFW also provides a list of CF clinics in e.g. Argentina,
Australia, Belgium, Canada, the Czech Republic, Cuba,
Denmark, Finland, France, Italy, Jordan, the Netherlands,
New Zealand, Norway, Romania, the Slovak Republic, South
Africa, Spain, Sweden, Switzerland and the United Kingdom.
However, some of the clinics included in this list may not
comply with the European Standard of CF care (http://www.
cfww.org/members/).
The European Cystic Fibrosis Society (ECFS) provides a list
of national CF associations and their web sites in Europe,
Canada, Australia, New Zealand, Russia and the United States.
Most of these web sites are in the respective national languages
(http://www.ecfs.eu). Moreover, CF centres in the United States
can be identified through the U.S. Cystic Fibrosis Foundation's
web site (http://www.cff.org).
There are many other sites providing information on CF
experts, clinics and CF associations. However, as with all web
sites in general, their data may not be up to date, and contact
partners change quickly. Therefore any addresses obtained from
the internet should be verified before travelling and possible
contacts discussed with the CF team.
2.8. CF health/travel insurance (incl. repatriation)
Treatment in foreign countries can be extremely expensive,
and it is important to be well-informed about possible costs and
their reimbursement when planning a trip abroad. There is nogeneral regulation applying to everyone in all countries. Costs
and reimbursement depend on the agreements between a
patient's home country and the respective destination country,
the regulations in both places, the type of treatment the patient
needs and his/her health insurance plan. Gathering information
prior to departure and scheduling enough time to acquire it is
therefore essential.
2.8.1. European Union, Iceland, Liechtenstein, Norway and
Switzerland
For EU citizens, treatment costs in any EUmember country, as
well as in Iceland, Liechtenstein, Norway and Switzerland, are
covered by their national health insurance. However, this usually
only includes those costs covered (reimbursed or partially
reimbursed) in the patients' home countries. Consequently patients
have to consider that expenses might be reimbursed only partially.
In order to receive care in the above countries, patients have
to obtain the European Health Insurance Card, which is issued
by the national health insurance companies. Depending on the
respective national regulations and the treatment patients
receive, they may have to pay for the treatment at the
destination (before or after receiving it) and will be reimbursed
later by their national health insurance, or the health care is
provided for free. If patients are in doubt about the extent of the
card's coverage for them, they are advised to contact their
country's health authorities prior to departure for detailed
information about what is covered and what will be reimbursed.
A supplementary private insurance may be worth considering.
The European Union's DG Employment, Social Affairs and
Equal Opportunities web site offers valuable information on the
European Health Insurance Card and medical treatment abroad,
as well as on various national contacts (http://ec.europa.eu/
social/main.jsp?catId=509&langId=en).
Another useful source of information is the United Kingdom's
National Health Service web site. It offers a country-by-country
guide on how to access health care or claim refunds during a visit
to countries in the European Union as well as Iceland, Norway
and Liechtenstein. Although it addresses persons insured by
the UK's NHS, this site provides valuable information for
anyone preparing a trip abroad (http://www.nhs.uk/NHSEngland/
Healthcareabroad/Pages/EEAcountries.aspx).
EU citizens can get free personalized advice from the
European Union's Citizens Signpost Service which provides
guidance and practical advice to citizens on specific problems
they encounter in the EU and its Internal Market. Experts will
clarify relevant rules, advise citizens on how to assert their
rights and obtain, redress and direct them towards the body
which can best help solve their problem (http://ec.europa.eu/
citizensrights/front_end/index_en.htm).
2.8.2. Travelling to non-EU countries
If travelling outside the European Union, patients need to
inquire with their national health authorities if there are any
bilateral agreements concerning health insurance. If there is no
such agreement or the coverage is not sufficient (which will
usually be the case), patients will have to look for a private
insurance plan.
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of CF, they should find out from their national health authorities
if the national health insurance scheme provides any special
regulations for chronically ill patients travelling abroad which
still might cover treatment expenses in the destination country.2.8.3. Repatriation
Insurance of the costs for repatriation has to be placed
nationally. In some countries there may be non-profit
organizations offering their members special services like
repatriation without former personal health check.In Europe the European Health Insurance Card (EHIC)
guarantees treatment to European citizens but some parts
of the costs may not be covered by the national health
insurance schemes. For travelling in non-European
countries in most cases the patients will have to contract
private health insurance plans. Finding suitable health
insurance for the coverage of CF and other treatment costs
and for repatriation can be tricky, and patients should
think about it carefully prior to departure.2.9. Specific documents (customs, forms, medical letter)
Several documents issued by the patient's CF clinic may be
helpful during travel and in emergencies:
A certificate for customs stating why the person needs a large
supply of drugs and medical devices abroad, among them syringesTable 3
Recommendations for drug storage.
Substance Storage recommendation
Antibiotics
Colistemethate p.i. Do not store above 25 °C
Tobramycin p.i. Store between 2° and 8 °C
Azithromycin No special storage conditions apply
Chloramphenicol Store in a cool, dry place
Doxycycline Store below 25 °C
Ciprofloxacin No special storage precautions
Flucloxacillin Store in a cool dry place
Inhaled therapies
Sodium chloride 0.45% No information
Dnase Store between 2° and 8 °C
Salbutamol nebs Store below 30 °C
Colistin
Tobramycine Store between 2° and 8 °C
Hypertonic saline 4.5% Store below 25 °C
Digestive medications
Pancreatic enzymes Do not store above 25 °C
Miscellaneous
Ursodeoxycholic acid • Store Urdox film coated tabs below 25 °C
• No special requirements for destolit or ursofa
Tranexamic acid Do not store above 25 °Cand needles. This document helps to cross borders and pass
medication through airport security checks. The document should
contain: patient's name and date of birth, general description (not
name) of the disease (“chronic pulmonary disease”), a list of
medication, approximate quantities needed and daily frequency, a
list of medical devices, physician's name and signature, stamp of
the physician/clinic to make the document official. A template of
such a certificate can be downloaded at http://ecorn-cf.eu/index.
php?id=265&L=8.
A detailed medical report in English facilitating treatment
abroad.
The document should contain: patient's name and date of
birth, address and contact details of the patient's CF clinic and
attending physician, name of the underlying disease and a short
description, the person's health status, known allergies, the
daily (physio)therapy, a list of medications, approximate
quantities needed and daily frequency, stamp of the physician/
clinic to make the document official. A template of such a
“medical report” can be downloaded at http://ecorn-cf.eu/index.
php?id=265&L=8.
A certificate for theme and attraction parks. In some theme
parks such as Euro Disney, people with a handicap or chronic
condition like CF can obtain a special pass granting them priority
access to attractions by enabling them (and usually one or more
accompanying person) to skip waiting lines. An official document
signed and stamped by a clinic and stating the condition or
handicap (from national health authorities) or a paper mentioning
the disease and the need to prevent long standing times and
dehydration are usually accepted in order to obtain this pass.
Patients should contact the park they intend to visit to find out
what its criteria are.Comments/side effects
Stable for 28 days at 25 °C or below
May cause photosensitivity
May cause photosensitivity
Short dated
• Brief exposure (up to 24 h) to up to 30 °C does not affect
stability, and drug may be returned to the fridge afterwards.
• Protect from light
Protect from light
Protect from light
• Protect from light
• Stable for 28 days at 25 °C or below
May cause bronchoconstriction
Urdox should be stored in original container
lk brand
Table 4
Drug photosensitivity.
Drug (in alphabetical order) Photosensitivity
Yes/No
Amoxicilin/Clavulanate No
Azitromycine and other macrolides
(erytromycine, klaritromycine)
Yes (but rare)
Cefuroxim and other cephalosporins (cefaclor, cefalexin) No
Ciprofloxacine Yes
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at hand when travelling:
insurance policy and data, address and contact partners of
insurance agency (national and private), contact data of care-
taking CF clinic, contact data of national patient association
any medical documents if necessary, important telephone
numbers in case of emergency.Chloramphenicol No
Dnase (Pulmozyme) No
Doxycycline Yes
Fat solubile vitamins (ADEK) No
Fluconazole Yes
Itraconazole Yes
NSAID (non steroid antiinflammatory drugs) Yes
Pancreatic enzyme supplements (Kreon) No
Sulfamethoxazol/Trimethoprim Yes
Tetracycline Yes
Voriconazole Yes
Comment: The list is not complete. If there is uncertainty about photosensitivity
of a drug the traveller should ask the CF doctor or pharmacist.
CF patients should always carry their CF specific
insurance and health information as well as all necessary
contact data.3. During the journey and on site
3.1. Transportation and storage of medications
If carrying medical supplies, such as medications, needles
and syringes, patients should always carry a letter from their
doctor describing the underlying disease and listing all supplies
and approximate quantities needed. See Section 2.9 for further
information.
All medicines and devices need special consideration on
flights. If devices which require needles are to be used on board,
patients have to carry their own disposal unit. If possible, all
medicines should be kept in hand luggage. If the quantities are
too large, patients are advised to keep enough medicines and
equipment in their carry-on baggage to last for up to one week
in case suitcases are lost in transit. Baggage holds for check-in
baggage may be below 0 °C, which may have consequences for
temperature sensitive medicines and might cause glass vials to
break. One option is to ask the airline if a larger bag may be
carried on or if a bag may be stowed at the gate when boarding.
Other respiratory-related equipment and devices (e.g.
nebuliser, CPAP, and BiPAP machines) might be carried but
not operated during the flight. For specific information on
oxygen supplementation devices see Section 2.4.
Specific storage of medicines at the travel destination
depends on many different factors and patients are advised to
check with their travel agencies or companies to ensure their
needs can be met. They should also take into consideration
before travelling that some of the medicines needed may not be
available in the destination country. A list of some commonly
used medications in CF along with information on stability and
storage is shown in Table 3. Please note that not every single
medication is covered in this overview. Patients are therefore
advised to consult with their doctor about specific questions
they may have.Some CF medication needs specific storage precautions.
The CF individual should discuss these specific
requirements with the CF centre pharmacist.3.2. Routine therapy and medication
For many people with CF, taking a break from everyday life
also means taking one from routine therapy. Each current
therapy should be adapted to the travel situation in consultation
with a CF specialist. If possible, equipment and medications
should be rationalized to ensure the best possible quality of life
while travelling, i.e. the treatment regimen should be reviewed to
optimize the benefits of travel balanced with the medical need
for each medication and treatment. Antibiotics can be taken
along as stand-bymedication. They can also be taken throughout
the trip as a prophylaxis for exacerbation. Patients should be
informed about possible side effects of the medications. (NB:
Some antibiotics and antimycotics may cause a severe
photosensitive rash, and patients are advised to use extra
protection such as sun block, a hat, etc. Table 4 provides an
overview of some drugs that may cause photosensitive reaction.)
The patient's diet at the destination may differ from the
one he/she is used to at home. For patients suffering from
pancreatic insufficiency, the adapted intake and dosage of
pancreatic enzymes at the destination should therefore be
discussed prior to departure. The same goes for patients with
diabetes mellitus that requires therapy. Increased movement
and potential alcohol consumption at the destination may lead
to an alteration of the blood sugar homeostasis. In this case, it
is important to prevent hyperglycaemia and hypoglycaemia,
and the patients should always have carbohydrates readily
available. Fellow travellers should always be informed about
diabetes mellitus, signs of hypoglycaemia, and appropriate
counteractions.CF medication may need adaptation according to
climate change.
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How much and what type of airway clearance is appropriate
while travelling should be discussed with the CF physiother-
apist. There may be some difficulty adhering to airway
clearance while travelling, especially if taking long-haul flights,
keeping long hours and constantly being on the move. Action
points should be given to improve adherence, e.g. asking
travelling companions to give reminders or assist with airway
clearance. Available evidence suggests that no airway clearance
regimen has been shown to be better than any other. In patients
who use bulky equipment for airway clearance, this evidence
would support using an alternative and equally effective regime
during travel. For example, a vest could be substituted with a
more portable device such as PEP, acapella or flutter.
Most nebuliser systems can be used in any country as long as
there is suitable power supply. Some can even be plugged into a
cigarette lighter or are battery-operated. A range of systems are
available that make travel abroad easier as they are portable and
lightweight; however, some do need an adapter. In general in
Europe (except for Cyprus, Gibraltar, and Malta), the voltage
for the nebuliser is not a problem (220 V) and a standard travel
plug adapter is all that is needed. If travelling to the USA, South
America, the Caribbean, Cyprus, Gibraltar, and Malta, a 110 V
nebuliser is needed. On long-haul flights, battery operated
compressors can be used on board, but it is important to check
with the airlines about this. Some airlines carry their own
compressors, but their use is not recommended for hygienic
concerns. In general, compressors should be carried as hand
luggage. Like other medications, nebulised drugs should be
carried as hand luggage as well in case of need during the
journey or in case of delay. A letter from the patient's CF clinic
stating the purpose of a nebuliser and compressor, and a list of
all medications is recommended for customs [44–46]. See
Section 2.9 for further information.Nebuliser and other equipment should be checked for
electrical compatibility.
For people with CF a sufficient supply with fluids and
salt should be provided when travelling and especially
exercising in hot conditions. It is not sufficient to rely on
the patient's feeling of thirst and the salt content of
commercial drinks is usually not adequate.3.4. Prevention of salt depletion and dehydration
Physical activity has been recognised as beneficial to patients
with CF. When exercising in the heat, patients have to take into
account potential risks. A low tolerance of CF patients to
climatic heat stress has been described [47–49]. Because they
have up to three times higher concentrations of sodium and
chloride in their sweat, serum osmolality becomes lower
compared to healthy controls when exercising in hot conditions
and drinking pure water [50]. This relative hypoosmolality
deprives the patients of a trigger from thirst, leading to an
underestimation of their fluid needs and “voluntary dehydration”
[51].
Prevention of dehydration should be achieved through high
salt intake [52] and regular fluid replenishment rather than
relying on patient's thirst. One hour before exercising, CFpatients should drink 400–600 ml of fluids [53]. During
prolonged activities, 200–300 ml should be consumed every
15–20 min [53]. If activities last 45 min or less, fluid intake can
be postponed until after the training. Under warm or hot
conditions, there is an increased risk of salt loss and
dehydration, requiring additional fluid intake [54]. Oral
rehydrants containing from 4% up to 12% carbohydrates, a
sodium chloride concentration of 50 mmol/l (equal to 2.9 g of
salt per litre), as well as potassium and bicarbonate are useful
and should be prescribed to all CF patients for travel abroad. It
has to be taken into account that most commercial drinks
contain only 18 mmol/l sodium chloride (equal to about 1 g salt
per litre). However, it has been shown that only drinks with a
salt content of 50 mmol/l enhanced drinking and attenuated
voluntary dehydration [52]. Therefore, individuals with CF are
advised to add a pinch of salt to their beverages [53] or to
consume commercially available energy drinks containing salt
supplements. Salt replacement following exercise might also be
augmented by slow release tablets such as Slow Sodium
(600 mg), which contain 10 mmol of sodium chloride in an
enteric-coated tablet. The prescription for adults is usually
1200 mg twice a day when going to a hot destination. This
dosage can be increased to four times a day (max. dose 20
tablets/day), depending on the temperature and the amount the
individual patient perspires [55]. However, the tablets may
cause gastric discomfort and are not suitable for use during
exercise. In addition to the above, patients should eat salty
snacks and keep themselves mobile, especially on long-haul
flights. Due to the low humidity on board, there is an increased
risk of dehydration during air travel. This, together with
decreased mobility during the flight, constitutes an increased
risk of deep venous thrombosis, with the danger of pulmonary
artery embolism. Relative contraindications to high volume
load in patients with liver cirrhosis with ascites must be
respected.
Diabetics in particular are in danger of fluid loss and
dehydration in hot regions. Additional fluid loss in cases of
diarrhoea and vomiting should be balanced by taking electrolyte
solutions in order to prevent DIOS.3.5. Physical activities and sports
Just like healthy people, many CF patients use their holidays
and leisure time for outdoor physical activities and sports. It is
indisputable that such activities have a favourable influence on
many aspects of CF. Active travel involving sports such as
skiing, snowboarding, water sports, scuba diving, or bungee
jumping are becoming increasingly popular. As there are no
systematic investigations on the different kinds of CF-specific
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based recommendations can be made at this point in time. The
following recommendations are mainly based on case reports
and are therefore anecdotal; however, patients should be made
aware of these hazards before attempting some of these
activities (see Table 5, a shorter version of “Potential
complications of sports activities” at http://ecorn-cf.eu/index.
php?id=265&L=8).
Exercise-induced hypoxemia: Altitude can lead to a decrease
of oxygen saturation in the blood, therefore winter sports and
climbing at high altitudes are not recommended for patients
with a decrease in oxygen saturation below 90% during exercise
test [55]. Episodes of acute right heart failure at high altitude are
well documented [55,56]. It is advisable to do an ergometry
with every patient before starting a sports program and to
include one in the annual check-up program. No monitoring is
needed in patients with a normal result of the incremental
maximal exercise test [53]. Exercise that leads to a decrease in
oxygen saturation of more than 5% or below 90% should be
avoided [57,58]. Patients with an oxygen saturation below 90%
at rest are at risk of worsening and should not engage in physical
activities without supplemental oxygen and close supervision of
oxygen saturation during exercise.Table 5
Potential complications of sports activities. Please note that this table is only
supposed to provide a basic overview of the risks involved in some of the most
popular types of sports. A more detailed table including specific
recommendations is available for download at http://ecorn-cf.eu/index.php?
id=265&L=8. In general, exercise is beneficial, but patients are strongly advised
to consult with their doctor about potential complications resulting from their
sport of choice in their specific health condition.
Sports Complications
Ball sports Bleeding from oesophageal varices
Soccer, volleyball, tennis, etc. Rupture of liver and spleen
Fractures (esp. in team sports)
Pneumothorax (Tennis)
Contact sports Bleeding from oesophageal varices
Judo, karate, etc. Rupture of liver and spleen
Fractures (esp. in team sports)
Water sports Pseudomonas (in pools, etc.)
Swimming, scuba diving, etc. Pneumothorax (diving)
Extreme sports Pneumothorax
Bungee jumping, parachuting,
free climbing, etc.
Bleeding from oesophageal varices
Rupture of liver and spleen
Fractures
Exercise-induced hypoxemia
(climbing at high altitude)
Acute right heart failure
(climbing at high altitude)
Winter sports Exercise-induced hypoxemia
Acute right heart failure
Pulmonary exacerbation
Horse riding ABPA
Pseudomonas
Strength training Pneumothorax
with high loads Haemoptysis
Sprinting Haemoptysis
Endurance training Hypoglycaemia in diabetes
Dehydration and hyponatriaemia
Sauna/Hot tubs PseudomonasBronchoconstriction: There is some data showing a bronchial
hyperreactivity in CF patients, which is mostly induced by
provocation with chemical agents. Whether or not exercise itself
induces bronchoconstriction in CF patients is less clear. For some
patients with a history of exercise-induced bronchoconstriction,
positive effects can be achieved through the use of beta-2-agonists
before exercise. The effect of such a therapy should be evaluated
prior to travelling [53].
Pneumothorax: Patients with advanced lung disease should
not engage in sports that require press breathing or rapid and
jerky movements of the upper body (e.g., tennis, volleyball, and
bungee jumping). Deep-sea and scuba diving is contraindicated
in patients with air trapping, which may lead to pneumothorax
on ascent or aggravation of sinus disease [55,59]. As air
trapping can be seen even in clinically healthy CF patients and a
pneumothorax under water is a potentially life-threatening
situation, it seems reasonable to disadvise CF individuals to
actively engage in scuba diving.
Haemoptysis: Patients with bronchiectasis and a history of
haemoptysis should avoid those types of sports with a strong
increase in breathing or blood pressure (e.g., sprinting, strength
training with heavy loads); oxygen supplementation during
training might reduce the risk in patients with exercise-induced
hypoxaemia, as it can reduce the breathing volume per minute
for a given strain [53].
Right heart failure: In patients with increased right heart
strain, physical activity and sports could lead to acute cor
pulmonale, heart insufficiency or ventricular arrhythmias
[59,60]. Physical activities at high altitude are not recom-
mended for CF patients who are already hypoxic, as aerobic and
anaerobic exercises at altitude cause episodes of right heart
failure. Two cases of cor pulmonale requiring heart and double
lung transplantation after strenuous exercise during holidays at
altitude have been reported in the literature [56]. In the presence
of chronic cor pulmonale, physical activities should be
performed cautiously and under strict supervision [59].
Hypoglycaemia: Physical activities and endurance training
can result in significant decrease in blood glucose, particularly
in patients who are on insulin or oral anti-diabetics therapies.
There are also sporadic reports of hypoglycaemia following
exercise in non-diabetic patients. It is recommended that
patients have a meal rich in carbohydrates before exercise and
adjust their insulin doses [53]. During prolonged moderate to
heavy exertion, patients with diabetes should frequently
measure their blood glucose level.
Bleeding: As life expectancy is increasing, the prevalence of
adult patients with advanced liver disease (cirrhosis, impaired
plasmatic coagulation) increases. Sports with acute changes of
pressure in the abdomen or thorax (e.g., contact sports with risk
of blows in the abdomen like soccer, judo, and karate) or
changes of blood pressure (e.g., strength training with heavy
weights, etc.) are associated with the risk of rupture of liver and/
or spleen, as well as gastrointestinal bleeding from oesophageal
varices [55].
Fractures: Many older CF patients show a significant
reduction of bone density. Patients who are playing sports
where the risk of fracture may be considerably increased should
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of over- and downthrow (e.g., contact sports and some martial
arts, bungee jumping, and parachuting) are not recommended
[61–63].Some sports have specific risks—some health condi-
tions preclude specific sports. The risk associated to
specific sports activities should be discussed between
the individual with CF and the CF centre.3.6. Prevention of P. aeruginosa infection
Although acquiring P. aeruginosa is not an issue specific to
travel it is nevertheless a major concern for many patients when
taking a trip. As in daily life, the possibility of acquiring
P. aeruginosa or other CF-relevant bacteria during travelling
cannot be completely avoided. The general concern of lower
hygienic standards abroad (e.g. bacterial load of sanitary
facilities, swimming pools) seems to be of importance.
However, the basic hygienic recommendations and precautions
CF patients should follow abroad are somewhat similar to those
at home. It has to be kept in mind that evidence for most
recommendations below is modest at best.
3.6.1. From the environment
Most water reservoirs are natural habitats of P. aeruginosa,
including sea shores, lakes and rivers. However, there is
ongoing controversy about to what extent these sources pose a
risk of CF-related lung infection. Whether or not the use of
swimming pools should be discouraged is also under debate.
Most CF centres allow their patients the use of public pools that
are certified by local health authorities. However, the risk of
bacterial transmission might be related to the practice used for
water disinfection, which differs throughout Europe: The
prevalence of P. aeruginosa in public swimming pools was
reported to be 4–7% in Switzerland [64]. In contrast, a study
from Northern Ireland detected P. aeruginosa in up to 38% of
public swimming pools [65]. In the latter study, the prevalence
of P. aeruginosa was even higher in private pools and jacuzzis
(whirlpools) (72%). There was a similar trend in respect to
public and private hydrotherapy pools. Therefore, CF patients
should weigh the risk before using private pools or spas.
P. aeruginosa can often be isolated from the peel of fresh fruit,
vegetables, and salads. Therefore, it is recommended that patients
with CF wash, peel or cook vegetables before consumption.
Many animals are known carriers of P. aeruginosa too, such
as nematodes, minks, dolphins, and horses. The latter frequently
carry P. aeruginosa in their noses, and there is a risk of
transmission during horse riding [66]. Also, acquisition of
Aspergillus spp. from stable manure has been reported.
3.6.2. Patient-to-patient transmission
In contrast to the environmental sources described above,
transmission of bacteria between CF patients is well character-
ized. In the past, it was found beneficial for CF patients toengage in social activities, such as summer camps, together.
Positive effects of such camps on patient exercise tolerance,
nutritional status, and well-being were reported [67]. This
attitude has changed since evidence of cross-infection of
bacteria, particularly P. aeruginosa and B. cepacia has come
to light. Nowadays, the risk of cross-infection is thought to
outweigh the possible benefits and CF summer camps have
been discontinued [4,68–70].
However, when attending events with other CF patients, it is
important to minimise the possibility of cross-infection by
following certain hygienic guidelines (please see http://cfww.
org/docs/conferences/2009/hygiene_guidelines.pdf). [71]. There
is broad consensus that individuals who have cultured positive
with Burkholderia cepacia complex, Methicillin resistant Staph.
aureus (MRSA) or other panresistant bacteria should not be in
close contact with other CF patients or attend CF events [72].CF
patients should discuss cross-infection issues with their physician
and make an informed decision about whether to engage in social
activities with other CF-patients or not.
4. Specific recommendations for immunocompromised
travellers/organ recipients
Immunocompromised CF patients after lung or liver trans-
plantation need special advice before travelling.While no specific
literature regarding travellers who received a lung or liver
transplant is available, there are reports that focus on risks and
recommendations for immunocompromised travellers, including
solid organ recipients. Three basic problems have to be
distinguished here: first, increased susceptibility to travel-related
diseases and opportunistic infections; second, drug interactions
between routine medication (e.g., immunosuppressants) and
concomitant medication for travel-related illnesses (e.g., malaria
prophylaxis); and third, concerns regarding vaccine use (e.g.,
safety of live vaccines, potentially decreased vaccine efficacy).
4.1. Diseases related to travel
Most commonly, travel-related diseases are foodborne
infections associated with food handling practices. Some
specific bacterial infections, such as non-typhoidal Salmonella
spp., Shigella spp., Campylobacter spp. and Microsporidia, are
more severe in immune suppressed hosts [73–75]. While
recognizing the limitations of “food and water precautions,”
immunocompromised travellers should be advised to follow
them rigorously, e.g. by having hot meals in restaurants, taking
water precautions (bottled, boiled, and filtered), and avoiding
unpasteurized milk products. Every immune suppressed
traveller, particularly those with pre-existing renal dysfunction
or on nephrotoxic medication (e.g., Cyclosporin A), should be
aware of the importance to maintain hydration and options of
oral rehydration. Prophylactic antimicrobial agents are not
routinely recommended but might be used for a limited period
of time. Patients should carry a stand-by supply of antibiotics
(e.g., Ciprofloxacin, Azithromycin, and Metronidazol) and be
advised to start medication early in the case of fever or
diarrhoea. The threshold for seeking qualified medical advice
397T.O. Hirche et al. / Journal of Cystic Fibrosis 9 (2010) 385–399and discontinuation of vacations in case of deterioration of
health should be set low.Immunocompromised CF patients should be carefully
advised to avoid risk of opportunistic infections.4.2. Drug interactions
Many routine drugs prescribed to transplant recipients
interact with drugs that are metabolized by CYP3A4 system.
For example, malaria prophylaxis with chloroquine increases
serum levels of Cyclosporin A, FK 506 (tacrolimus), or
Rapamycin. However, the data on interactions between anti-
rejection drugs and most travel-associated drugs are limited. It is
recommended that patients start concomitant medications (e.g.,
malaria prophylaxis) several weeks prior to travelling in order to
monitor and adapt the serum levels of immunosuppressants.
4.3. Vaccination under immunosuppression
Any recent or present immunosuppressive treatment includ-
ing oral corticosteroids longer than one month with high doses
may compromise the efficacy of any vaccine and may be a
danger in live vaccines of contracting the disease. Inhaled
steroids, except in very high doses, are not a contraindication to
vaccine administration [5].
Following lung or liver transplantation, any proposed
vaccine should be considered from two perspectives: safety as
well as the possibility of decreased effectiveness in the context
of the underlying immunosuppression. In general, live vaccines
should strictly be avoided in the immunosuppressed CF patient.
Varicella vaccine, oral poliomyelitis vaccine, measles–mumps–
rubella vaccine, yellow fever vaccine and BCG are the most
common live vaccines. However, the risk of the exposures of
the disease must be balanced against the risks of vaccination,
and the individual's degree of immunosuppression. Therefore it
is very important for any future transplant candidates to have a
vaccination review before transplantation [5,76]. Scheduled
vaccinations should be completed at least two weeks before
transplantation.
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